Navigation Links
Lifestyle changes may stave off diabetes for a decade
Date:11/2/2009

Sustaining modest weight loss for 10 years, or taking an anti-diabetic drug over that time, can prevent or lower the incidence of type 2 diabetes in people at high risk for developing the disease, according to the Diabetes Prevention Program Outcomes Study (DPPOS), a long-term follow-up to a landmark 2001 diabetes prevention study.

Jill Crandall, M.D., associate professor of clinical medicine at Albert Einstein College of Medicine of Yeshiva University, was a principal investigator in the follow-up study, which appears online in the current edition of the British medical journal the Lancet.

The original study ─ the Diabetes Prevention Program (DPP) ─ was a large, randomized trial involving 3,234 people at high risk for developing diabetes. At the start of the study, all were overweight or obese adults with elevated blood glucose levels. Researchers disclosed the findings from DPP in 2001 ─ a year earlier than scheduled ─ because results were so clear. After three years, intensive lifestyle changes (modest weight loss coupled with increased physical activity) reduced the rate for developing type 2 diabetes by 58 percent compared with placebo. The oral diabetes drug metformin (850 milligrams twice daily) reduced the rate of developing diabetes by 31 percent compared with placebo.

Since these striking results were based on just three years of data, researchers could not determine how long the benefits would last. Following a seven-month bridge period after the original study ended, the follow-up DPPOS began, with 88 percent of DPP volunteers taking part. During the study pause, all participants learned the results and were offered 16 education sessions on making intensive lifestyle changes. The latest results, reflecting a full decade of participation ─ three in the DPP study and seven in DPPOS ─ indicate that lifestyle interventions producing even modest weight loss can significantly help to prevent or delay diabetes over the long term.

Specifically, for the 10 years spanning the DPP and DPPOS studies, the diabetes incidence (i.e., rate at which new diabetes cases were diagnosed) in the lifestyle group was reduced by 34 percent compared with placebo. For the group taking the diabetes drug metformin, diabetes incidence was reduced by 18 percent. Expressed another way, the lifestyle group delayed type 2 diabetes by about four years compared with placebo, and the metformin group delayed it by two years.

"The fact that we've continued to delay and possibly even prevent diabetes in people at very high risk for developing the disease is certainly a positive finding," says Dr. Crandall. She notes that those people randomly assigned to make lifestyle changes also had more favorable cardiovascular risk factors (including lower blood pressure and triglyceride levels) despite a reduction in drug treatment prescribed by their personal physicians.

The benefits of intensive lifestyle changes were especially pronounced among older people. Those aged 60 and over lowered their rate of developing type 2 diabetes in the next 10 years by about half.

The increase in the number of overweight Americans has led to an epidemic of type 2 diabetes that shows no signs of slowing. More than two-thirds of adults are now overweight or obese. About 11 percent of adults ─ 24 million people ─ have diabetes, and up to 95 percent of them have type 2 diabetes, according to the National Institutes of Health. Diabetes is a major cause of heart disease and stroke and the major cause of kidney failure, limb amputations and new-onset blindness.

The researchers are now analyzing the DPPOS data to see whether clinical outcomes differ among the three groups. "The long-term weight loss and reduction in diabetes that we observed in DPPOS are encouraging," says Dr. Crandall. "But ultimately, establishing the benefits of preventing diabetes means showing that you can reduce the deaths and the severe complications associated with this disease."


'/>"/>

Contact: Deirdre Branley
sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Related biology news :

1. Genomes reveal bacterial lifestyles: Research
2. American College of Preventive Medicine releases lifestyle medicine literature review
3. Modern lifestyle prevents tooth decay
4. Scientists reveal the lifestyle evolution of wild marine bacteria
5. Diet and lifestyle critical to recovery, says study
6. SAGEs American Journal of Lifestyle Medicine looks at the health benefit of oats
7. Changes in brain chemicals mark shifts in infant learning
8. Studies improve knowledge of underlying brain changes caused by addiction
9. Queens scientists on international team discover ecologically unique changes in Arctic lake
10. Arctic lake sediments show warming, unique ecological changes in recent decades
11. PETAs push for changes in USDA testing pays off for animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... 2017 Research and Markets has announced the ... to their offering. ... eye tracking market to grow at a CAGR of 30.37% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
Breaking Biology News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Eli Lilly and Company ... data evaluating galcanezumab for the prevention of migraine at ... will take place April 22-28, 2017, in ... four abstracts at AAN, including safety and patient outcomes ... associated with a reduction in monthly migraine headache days ...
(Date:4/20/2017)... , ... April 20, 2017 , ... ... sources for advanced technology applications, announced today that Chief Executive Officer (CEO) Debbie ... SEMI is the global industry association connecting the electronics manufacturing supply ...
(Date:4/20/2017)... , April 20, 2017 For ... focuses on novel drug development and clinical research aimed at ... Biostage Inc. (NASDAQ: BSTG), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Kite ... ZIOP ). You can access our complimentary research reports ... ...
(Date:4/19/2017)... ... April 19, 2017 , ... Nobilis Therapeutics Announces Completion of Landmark ... Clinical Data in its Upcoming Post Traumatic Stress Disorder Trial , Nobilis Therapeutics, ... trial assessing efficacy of its NBTX-001, a xenon-based therapeutic in the treatment of Panic ...
Breaking Biology Technology: